Vitamin D for Immune Function

Vitamin D began as a bone nutrient and became an immune one when researchers noticed that almost every immune cell type expresses the vitamin D receptor, and that macrophages can activate the vitamin locally rather than waiting for the kidney to do it. That is not the behaviour of a bystander nutrient. The clinical translation has been messier than the biology suggested. Individual trials have often been null, while pooled analyses that separate deficient from replete participants tell a more coherent story.

The pattern across the respiratory infection literature is that daily or weekly supplementation produces a small overall reduction in acute respiratory infection risk, with the benefit concentrated in people who were deficient at baseline and largely absent with infrequent high-dose bolus regimens. In practice this means vitamin D is a correction of a deficit rather than an immune enhancer for people who already have adequate levels.

The clearest innate mechanism is antimicrobial peptide induction. Calcitriol binding to the vitamin D receptor drives transcription of cathelicidin and beta-defensin in monocytes and epithelial cells — peptides that disrupt bacterial and viral membranes directly at the mucosal surface where respiratory infections begin.

On the adaptive side the effect is regulatory rather than stimulatory. Calcitriol shifts T cell differentiation away from Th1 and Th17 phenotypes and towards regulatory T cells, and dampens dendritic cell antigen presentation. This is why vitamin D is studied both for infection resistance and for autoimmune conditions — the same immunomodulatory action serves both. Macrophages express 1-alpha-hydroxylase, letting them convert circulating 25-hydroxyvitamin D to the active form locally. That is the reason circulating 25(OH)D status, rather than kidney-produced calcitriol, is what predicts immune outcomes.

Daily dosing outperforms large intermittent boluses for immune outcomes, and the target is a blood level rather than a pill count. Most adults reach sufficiency on 1000 to 2000 IU daily; testing 25(OH)D is worthwhile before using higher doses, and repletion protocols should be medically supervised.

The evidence base for this pairing is large but heterogeneous. Individual participant data meta-analyses of randomised trials in acute respiratory infection have reported small but statistically significant protective effects, driven by trials using daily or weekly dosing and by participants with low baseline 25-hydroxyvitamin D. Trials in already-replete populations and those using single high-dose boluses have generally been null. No pair-specific studies are currently linked to this page, so no study list is displayed. Citations are pending editorial review and will appear here once the underlying trials are attached to the pairing rather than inferred from the wider literature.

Vitamin D3 at maintenance doses has an excellent safety record. Toxicity is real but requires sustained intake far above normal supplementation — typically tens of thousands of IU daily over months — and presents as hypercalcaemia with nausea, excessive thirst, confusion and kidney stones.

Two categories matter: drugs that accelerate vitamin D breakdown, lowering your effective dose, and drugs whose toxicity increases when calcium rises.